Search Results - "Silva, Milton Barros e"

Local therapy in advanced melanoma after immune checkpoint inhibitors aiming to achieve complete response by de Barros e Silva, Milton, Teixeira, Marcos, Lobo, Matheus, Molina, André, Bertolli, Eduardo, Santos Filho, Ivan, Castro Ribeiro, Heber, Pelizon, Antônio, Lopes Pinto, Clóvis, Duprat Neto, João

“…Background and Objectives: New scenarios for local therapy have arisen after starting immune checkpoint inhibitors (ICIs) to treat advanced melanoma (AM). The…”
Get full text

Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer by de Brito, Germana Alves, Junior, Antonio Paulo Nassar, Silva, Milton Barros e, Bettim, Barbara Beltrame, Pereira, Benedito Jorge

“…Background and objectives Acute kidney injury (AKI) has emerged as an important toxicity among patients with advanced cancer treated with immune checkpoint…”
Get full text

Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies by de Jesus, Victor Hugo Fonseca, Felismino, Tiago Cordeiro, de Barros e Silva, Milton José, de Souza e Silva, Virgílio, Riechelmann, Rachel P

“…Noncolorectal gastrointestinal (GI) malignancies are among the most frequently diagnosed cancers. Despite the undeniable progress in systemic treatments in…”
Get full text

Role of Annexin A1 Secreted by Neutrophils in Melanoma Metastasis by Sandri, Silvana, Hebeda, Cristina Bichels, Broering, Milena Fronza, de Paula Silva, Marina, Moredo, Luciana Facure, de Barros E Silva, Milton José, Sapata Molina, André, Lopes Pinto, Clóvis Antônio, Duprat Neto, João Pedreira, Reutelingsperger, Chris P, Gil, Cristiane Damas, Farsky, Sandra Helena Poliselli

“…Annexin A1 (AnxA1) is highly secreted by neutrophils and binds to formyl peptide receptors (FPRs) to trigger anti-inflammatory effects and efferocytosis. AnxA1…”
Get full text

Tuberculosis in a patient on temozolomide: a case report by de Paiva, Tadeu Ferreira, de Barros e Silva, Milton José, Rinck, José Augusto, Fanelli, Marcello Ferreti, Gimenes, Daniel Luiz

“…Temozolomide (TMZ) is a cytotoxic agent of the imidazotetrazine class, chemically related to dacarbazine. Its use poses higher risks of lymphopenia and…”
Get full text

Immune mechanisms and predictive biomarkers related to neoadjuvant immunotherapy response in stage III melanoma by Figueiredo, Amanda Braga, Barros e Silva, Milton José, Evangelista, Guilherme Ferreira de Britto, Galdino, Nayane Alves de Lima, Kuil, Larissa de Melo, Santos, Iasmim Polido, Morais, Kátia Luciano Pereira, Cavalcanti, Clara Maciel, Moredo, Luciana Facure, Duprat-Neto, João Pedreira, Gollob, Kenneth J

“…The treatment for stage III melanoma has advanced significantly, nevertheless, a substantial proportion of patients experience relapse. Neoadjuvant immune…”
Get full text

Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST by de Azevedo, Carla Rameri Alexandre Silva, Paiva, Tadeu Ferreira, Rossi, Benedito Mauro, Guimarães, Gustavo Cardoso, de Souza Begnami, Maria Dirlei Ferreira, Oliveira, Thiago Bueno, Barros e Silva, Milton José, Fanelli, Marcello Ferretti, de Mello, Celso Abdon Lopes

“…There are few data that show pathologic complete response (pCR) to imatinib treatment in gastrointestinal stromal tumors (GISTs). We describe a case of a…”
Get full text

Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors by de Britto Evangelista, Guilherme Ferreira, Figueiredo, Amanda Braga, de Barros e Silva, Milton José, Gollob, Kenneth J

“…Immune checkpoint inhibitors (ICI) have provided new hope for cancer patients, and in particular for patients with tumors that are immunologically active and…”
Get full text

Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas by Chiappini, Paula Blandina Ola, de Medeiros, Ivan Ucella Dantas, Lima, Luiz Guilherme Cenaglia, Fregnani, Jose Humberto, Nonogaki, Suely, da Costa, Jr, Wilson Luiz, Coimbra, Felipe Jose Fernandez, Silva, Milton Jose de Barros E, de Mello, Celso Abdon Lopes, Pinto, Clovis Antonio Lopes, Begnami, Maria Dirlei

“…Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway plays a critical role in carcinogenesis and resistance to anticancer drugs. In this study,…”
Get full text

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil by de Melo, Andreia Cristina, Karen de Sá, Vanessa, Sternberg, Cinthya, Olivieri, Eloisa Ribeiro, Werneck da Cunha, Isabela, Fabro, Alexandre Todorovic, Carraro, Dirce Maria, de Barros e Silva, Milton José, Pimenta Inada, Haynna Kimie, de Mello, Evandro Sobrosa, Soares, Fernando Augusto, Takagaki, Tereza, Ferreira, Carlos Gil, Capelozzi, Vera Luiza

“…To show additional prognostic information about the mutational profile and new International Association for the Study of Lung Cancer/American Thoracic…”
Get more information

BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES by Torres, Orlando Jorge Martins, Marques, Márcio Carmona, Santos, Fabio Nasser, Farias, Igor Correia de, Coutinho, Anelisa Kruschewsky, Oliveira, Cássio Virgílio Cavalcante de, Kalil, Antonio Nocchi, Mello, Celso Abdon Lopes de, Kruger, Jaime Arthur Pirola, Fernandes, Gustavo Dos Santos, Quireze, Jr, Claudemiro, Murad, André M, Silva, Milton José de Barros E, Zurstrassen, Charles Edouard, Freitas, Helano Carioca, Cruz, Marcelo Rocha, Weschenfelder, Rui, Linhares, Marcelo Moura, Castro, Leonaldson Dos Santos, Vollmer, Charles, Dixon, Elijah, Ribeiro, Héber Salvador de Castro, Coimbra, Felipe José Fernandez

“…In the last module of this consensus, controversial topics were discussed. Management of the disease after progression during first line chemotherapy was the…”
Get full text

Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition by De Barros E Silva, Milton Jose, Tavares, Monique Celeste, Lima, Joao Paulo S. N., Garcia, Daniel, Molina, Andre, Lobo, Matheus, Pinto, Clovis Antonio Lopes, De Paula, Rafaela Brito, Rinck Jr, Jose Augusto, Duprat Neto, João Pedreira

“…e21563 Background: Perioperative pembrolizumab to advanced melanoma, as shown SWOG S1801 trial, was associated with a longer event-free survival (EFS) than…”
Get full text

Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma by De Barros E Silva, Milton Jose, Tavares, Monique Celeste, Lima, Joao Paulo S. N., Garcia, Daniel, Rinck Jr, Jose Augusto, Molina, Andre, Lobo, Matheus, Pinto, Clovis Antonio Lopes, De Paula, Rafaela Brito, van Akkooi, Alexander Christopher Jonathan, Duprat Neto, João Pedreira

“…9590 Background: Accurate identification of pathological response to neoadjuvant therapy for clinical stage III melanoma before surgery may allow us to better…”
Get full text

Clinical characteristics and treatments outcomes of patients with metastatic uveal melanoma (UM) in a Brazilian population: A retrospective unicentric study by Campiolo, Giovanna, De Barros E. Silva, Milton Jose, Petaccia de Macedo, Mariana, Rinck, Jose Augusto

“…Abstract only e21018 Background: Uveal melanoma is the most common primary ocular tumor in adults and accounts for 5% of all melanoma diagnoses in the United…”
Get full text

Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation by Chanson, Noémie, Ramos-Casals, Manuel, Pundole, Xerxes, Suijkerbuijk, Karijn, José de Barros e Silva, Milton, Lidar, Merav, Benesova, Karolina, Leipe, Jan, Acar-Denizli, Nihan, Pradère, Pauline, Michot, Jean-Marie, Voisin, Anne- Laure, Suárez-Almazor, Maria E., Radstake, Timothy R.D., Fernandes Moça Trevisani, Virginia, Schulze-Koops, Hendrik, Melin, Audrey, Robert, Caroline, Mariette, Xavier, Baughman, Robert P., Lambotte, Olivier, Ramos-Casals, Manuel, Mariette, Xavier, Lambotte, Olivier, Kostine, Marie, Khamashta, Munther A., Calabrese, Leonard, Suárez-Almazor, Maria, Baldini, Chiara, Bingham, Clifton O., Gottenberg, Jacques-Eric, Radstake, Timothy R.D., Schaeverbeke, Thierry, Schulze-Koops, Hendrik, Brito-Zerón, Pilar, Flores-Chávez, Alejandra, Acar-Denizli, Nihan

“…To analyse the clinical patterns of sarcoidosis triggered by immune checkpoint inhibitors (ICIs) in patients with cancer. The ImmunoCancer International…”
Get full text

FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma by De Barros E Silva, Milton Jose, Tavares, Monique Celeste, Lima, Joao Paulo S. N., Buzaid, Antonio C., Garcia, Daniel, Camargo, Veridiana Pires De, Molina, Andre, Bertolli, Eduardo, Lobo, Matheus, Van Akkooi, Alexander Christopher Jonathan, Pinto, Clovis, De Paula, Rafaela Brito, Lima, Eduardo, Rinck, José Augusto, Duprat, Joao

“…9585 Background: Neoadjuvant immunotherapy with nivolumab 3mg/kg and ipilimumab 1 mg/kg (N3+I1) for two cycles for clinical stage III melanoma have shown rates…”
Get full text

Adjuvant therapy in non-metastatic melanoma result from a Brazilian cohort by Silva, Sinara Figueiredo, Tavares, Monique Celeste, De Barros E Silva, Milton Jos, Rinck, José Augusto, Lima, Joao Paulo SN, Garcia, Daniel, Calsavara, Vinicius Fernando

“…Abstract only e22095 Background: The PD-1–blocking antibodies, combination of target therapy and anti-CTLA4 have shown a favorable safety profile with better…”
Get full text

18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience by Liz, Caio Dabbous, Teixeira, Marcos Rezende, Mendes Gomes Siqueira, Luciana Beatriz, Rinck, Jose A., Lima, Joao Paulo S. N., Tavares, Monique Celeste, Garcia, Daniel, Oliveira, Thiago Bueno, Cavicchioli, Marcelo, Lima, Eduardo, Duprat, Joao, De Barros E. Silva, Milton Jose

“…Abstract only e21533 Background: Combination therapy with anti-PD1 and low-dose ipilimumab has shown reduced rate of immune-related adverse effects compared…”
Get full text

Total tumor burden as predictive tool of response and survival of patients with metastatic melanoma treated with nivolumab by Barros e Silva, Milton Jose, Salgado Boneti, Bianca, de Moares, Rafael

“…Abstract only 48 Background: Nivolumab (NIVO) has shown increased results either in objective response rate (ORR), progression free survival (PFS) and overall…”
Get full text

Bone metastasis as an independent prognostic factor for survival in patients with advanced melanoma treated with immune checkpoint blockade by Teixeira, Marcos Rezende, De Barros E Silva, Milton Jos, Pandolfi, Natasha Carvalho, Calsavara, Vinicius Fernando, Oliveira, Thiago Bueno, Tavares, Monique Celeste, Rinck, José Augusto, Garcia, Daniel, Lima, Joao Paulo SN, Duprat, Joao

“…Abstract only e22045 Background: Immune checkpoint blockade (ICB) has changed the natural history advanced melanoma (AM) with response rates about 40% and…”
Get full text